ExomeNext®-*Trio*
Sequencing and Analysis of the Exome

SAMPLE REPORT

Ambry Genetics®
A TEMPUS COMPANY

PATIENT
Legal Name: **Patient, Sample**
Accession #: 00-306909
DOB: 10/08/2021
Sex Assigned at Birth: Male
MRN: N/A
Indication: Diagnostic

TEST INFORMATION
Portal Order #: 0000000
Family #: 0000000
Specimen #: N/A
Specimen type: Blood EDTA
Collection date: 12/01/2025
Received date: 12/01/2025
Test Started: 12/01/2025
Final Report: 01/01/2026

MEDICAL PROFESSIONAL
Sample Doctor
Sample Facility

ADDITIONAL RECIPIENTS
Sample Genetic Counselor

POSITIVE: Clinically Relevant Variant Detected

Reportable Findings		
Single gene variants	**Contiguous gene deletions/duplications**	**Mitochondrial genome**
1(1)*	**None**	**Not Ordered**

* genes(variants)

Indication for Testing
Autism, global developmental delay, hypotonia

Results

Gene (RefSeq ID)	Characterized/ Uncharacterized Gene	Relevant Associated Syndrome	Mode of Inheritance	Genotype	Variant	Variant Classification
CHD2 (NM_001271)	Characterized	*CHD2*-related developmental and epileptic encephalopathy	Autosomal dominant	Heterozygous, *de novo*	c.443+1G>A	Pathogenic Mutation

Interpretation

- **Overall, the evidence suggests that the identified *CHD2* variant is the cause of the patient's clinical symptoms.** Clinical correlation is recommended.

Notes
- If secondary findings were requested, results were issued in a separate report.
- Please note this assay is not intended to confirm previously detected copy number variants.
- Genetic counseling is a recommended option for all patients undergoing genetic testing.

Electronically Signed By Sample Director, on 01/01/2026 at 0:00:00 PM

All content hereafter is supplemental information to the preceding report.

Samples Received, Metrics, and Coverage

Family Member (Accession #)	Affected	Depth of coverage	
		% Bases ≥ 10x	% Bases ≥ 20x
Proband* (00-306909)	Yes	98.5	98.2
Mother* (00-306910)	No	98.4	98.0
Father* (00-306911)	No	98.5	98.2

*Exome sequencing performed. Coverage is only available for individuals with exome sequencing.
All family members with samples received are represented in this table. Complete coverage data for the proband can be e-mailed or made available for download through AmbryPort by request.

Analyses Performed

i) Full exome sequencing, bioinformatics, filtering and manual review based on dominant and recessive inheritance models was performed. Medical review of characterized genetic etiologies revealed a variant with likely clinical relevance.

ii) Because a characterized finding was identified, medical review of uncharacterized genes* and gene-disease relationships for potential candidate gene findings was not performed.

*Uncharacterized genes are not currently established to underlie Mendelian genetic conditions. An uncharacterized gene will be classified as a “candidate” when sufficient evidence, based on Ambry’s comprehensive, rule-based scoring criteria, is available (Farwell Hagman, 2017).

Raw Data

A table with additional variant filtering details can be found with the raw data filtered variant list (if requested). This list includes clinically irrelevant characterized genes and uncharacterized genes which could not be ruled out (if analyzed); these variants are not systematically confirmed via Sanger sequencing. The filtered variant list can be requested via this form (www.ambrygen.com/file/material/view/1262/Raw_Sequence_Data_Consent_0619_final.pdf).

CHD2 Gene Details

Gene Symbol	RefSeq ID	Genomic Coordinates (GRCh37)	Genomic Size (bp)	Total Exons	Coding Exons	Number of Amino Acids
CHD2	NM_001271	chr15:93443551-93571237	127687	39	38	1828 aa

The *CHD2* gene is located on chromosome 15q26.1 and encodes the chromodomain-helicase-DNA-binding protein 2. Pathogenic variants in this gene are known to cause *CHD2*-related developmental and epileptic encephalopathy, which is an autosomal dominant condition that generally occurs *de novo*. *CHD2*-related developmental and epileptic encephalopathy is characterized by early-onset refractory seizures and cognitive slowing or regression associated with frequent ongoing epileptiform activity, developmental delay, intellectual disability, and autism spectrum disorders. Seizure onset is typically between ages six months and four years, and seizure types include drop attacks, myoclonus, and rapid onset of multiple seizure types associated with generalized spike-wave on EEG, atonic-myoclonic-absence seizures, and clinical photosensitivity (Wilson, 2021). Loss of function has been reported as the mechanism of disease for *CHD2*-related developmental and epileptic encephalopathy.

CHD2 c.443+1G>A

Variant description:
The c.443+1G>A intronic variant results from a G to A substitution one nucleotide after exon 5 (coding exon 4) of the *CHD2* gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay.

Affected individuals:
This variant has been determined to be the result of a *de novo* mutation in an individual with *CHD2*-related developmental and epileptic encephalopathy (Yang, 2020).

Population frequency:
This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD).

Family inheritance:

Gene (RefSeq ID)	Variant	Exon	Proband (00-306909)	Mother (00-306910)	Father (00-306911)	Inheritance
CHD2[#] (NM_001271)	c.443+1G>A	Intron 5	Heterozygous	Negative	Negative	*De novo*[♦]

[#]Variant(s) detected via exome sequencing with Q-score and read depth above established confidence thresholds. Confirmation by automated fluorescence dideoxy sequencing (aka "Sanger") sequencing not performed.
[♦]Note that the possibility of germline mosaicism cannot be ruled out.

Based on the available evidence, the *CHD2* c.443+1G>A variant is classified as pathogenic.

Report References

- Wilson MM, *et al*. (2021) *Int J Mol Sci* **22**(2):588. **PMID:**33435571
- Yang JO, *et al*. (2020) *Front Genet* **11**:590924. **PMID:**33584793

Resources Used for Bioinformatics, Medical Review Filtering, and Reporting

- Ambry Genetics Variant Classification Scheme: http://www.ambrygen.com/variant-classification
- Chen S, *et al*. (2024) *Nature*. **625**(7993):92-100. **PMID**: 38057664. Genome Aggregation Database (gnomAD): https://gnomad.broadinstitute.org
- Choi Y, *et al*. (2012) *PLoS One*. **7**(10):e46688. **PMID**: 23056405
- Eppig JT, *et al*. (2012) *Nucleic Acids Res*. **40**(D1):D881-86. **PMID**: 22075990. Mouse Genome Database (MGD): https://www.informatics.jax.org/
- Farwell Hagman KD, *et al*. (2016) *Genet Med*. **19**(2):224-235. **PMID**: 27513193
- Feng BJ. (2017) *Hum Mutat*. **38**(3):243-251. **PMID**: 27995669
- Finger JH, *et al*. (2011) *Nucleic Acids Res*. **39**(Issue suppl_1):D835-D841. **PMID**: 21062809. Mouse Gene Expression Database (GXD): https://www.informatics.jax.org/
- Firth HV, *et al*. (2009) *Am J Hum Genet*. **84**:524-533. **PMID**: 19344873. Database of Genomic Variation and Phenotype in Humans using Ensembl Resources (DECIPHER): https://www.deciphergenomics.org
- Goldfarb T, *et al*. (2025) *Nucleic Acids Res*. **53**(D1):D243-D257. **PMID**: 39526381. RefSeq: http://www.ncbi.nlm.nih.gov/refseq
- Grantham R. (1974) *Science*. 1**85**(4151):862-864. **PMID**: 4843792
- Green RC, *et al*. (2013) *Genet Med*. **15**(7):565-74. **PMID**: 23788249
- Jaganathan K, *et al*. (2019) *Cell*. **176**(3):535-548.e24. **PMID**: 30661751
- Kanehisa M, *et al*. (2014) *Nucleic Acids Res*. **42**(D1):D199-205. **PMID**: 24214961. Kyoto Encyclopedia of Genes and Genomes (KEGG): http://www.genome.jp/kegg
- Karczewski KJ, *et al*. (2020) *Nature* **581**(7809):434-443. **PMID**: 32461654
- Kent WJ, *et al*. (2002) *Genome Res*. **12**(6):996-1006. **PMID**: 12045153. UCSC Genome Browser: https://genome.ucsc.edu
- Landrum MJ, *et al*. (2014) *Nucleic Acids Res*. **42**(D1):D980-5. **PMID**: 24234437. ClinVar: http://www.ncbi.nlm.nih.gov/clinvar
- Lane L, *et al*. (2012) *Nucleic Acids Res*. **40**(D1): D76-D83. **PMID**: 22139911. NeXtProt: http://www.nextprot.org
- Lee K, *et al*. (2025) *Genet Med*. **27**(8):101454. **PMID**: 40568962
- Lek M, *et al*. (2016) *Nature*. **536**(7616):285-91. **PMID**: 27535533
- Lin J, *et al*. (2019) Hum Mutat. **40**(10):1856-1873. **PMID**: 31131953
- Lindeboom RG, *et al*. (2016) *Nat Genet*. **48**(10):1112-8. **PMID**: 27618451
- MacDonald JR, *et al*. (2014) *Nucleic Acids Res*. **42**(D1):D986-92. **PMID**: 24174537. Database of Genomic Variants (DGV): http://dgv.tcag.ca
- Newman S, *et al*. (2015) *Am J Hum Genet*. **96**(2):208-20. **PMID**: 25640679
- Online Mendelian Inheritance in Man (OMIM®). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). http://www.omim.org
- Pagon RA, *et al*. editors. (1993-) Seattle, WA: University of Washington, Seattle. GeneReviews: http://www.ncbi.nlm.nih.gov/books/NBK1116
- Petryszak R, *et al*. (2013) *Nucleic Acids Res*. **42**(D1):D926-32. **PMID**: 24304889. Expression Atlas: http://www.ebi.ac.uk/gxa/home
- Rehm HL, *et al*. (2015) *N Engl J Med*. **372**(23):2235-2242. **PMID**: 2601459. Clinical Genome Clinical Validity Classifications: https://clinicalgenome.org/docs/clinical-validity-classifications
- Rhee J, *et al*. (2017) *Sci Rep*. **7**(1):1653. **PMID**: 28490743
- Richards S, *et al*. (2015) *Genet Med*. **17**(5):405-424. **PMID**: 25741868
- Richardson ME, *et al*. (2019) *Genet Med*. **21**(3):683-693. **PMID**: 30054569
- Rivas MA, *et al*. (2015) *Science*. **348**(6235):666-9. **PMID**: 25954003
- Smith ED, *et al*. (2017) *Hum Mutat*. **38**(5):600-608. **PMID**: 28106320
- Solomon BD, *et al*. (2013) *Proc Natl Acad Sci USA*. **110**(24):9851-5. **PMID**: 23696674. Clinical Genomic Database: http://research.nhgri.nih.gov/CGD
- Stenson PD, *et al*. (2014) *Hum Genet*. **133**(1):1-9. **PMID**: 24077912. Human Gene Mutation Database (HGMD®): http://www.hgmd.cf.ac.uk
- Thorvaldsdóttir H, *et al*. (2012) *Brief Bioinform*. **14**(2):178-192. **PMID**: 22517427
- Warde-Farley D, *et al*. (2010) *Nucleic Acids Res*. **38**(Issue suppl_2):W214-20. **PMID**: 20576703. GeneMANIA: http://genemania.org

ExomeNext® Assay Information

General Information: Ambry's ExomeNext® is a cost-effective, comprehensive, integrated whole exome sequencing assay designed to increase the diagnostic yield for genetic disorders that have eluded diagnosis using traditional diagnostic approaches. The exome represents all the protein-coding exons. It is estimated that exons contain about 85% of disease-causing variants. Whole-exome sequencing has been successfully applied to identify both inherited and *de novo* variants in a diverse variety of autosomal dominant, recessive, and X-linked disorders. In addition to the primary analysis, which is performed with the purpose of uncovering the underlying genetic cause for a given clinical presentation, the exome testing may also be utilized to detect secondary findings, which are pathogenic or likely pathogenic variants in select genes that lead to diseases unrelated to the patient's present clinical presentation.

Result Reports: A primary clinical report will only be generated for the proband regardless of number of family members submitted. However, it may be possible to infer information about family members' results based on the proband's report. Pathogenic variant(s) likely to factor into the patient's current clinical presentation are always reported as a relevant finding. Variants previously detected in the proband (not family members) that are provided at the time of testing will receive a report comment if the variant is detected by the assay (limit four variants in three genes). Copy number changes, somatic variants, and variants classified as benign or pseudodeficiency alleles are not eligible for comment. Common reasons a variant may not meet exome reporting criteria include inconsistent zygosity or inheritance, poor molecular support, and/or insufficient clinical overlap with the proband's reported features. Up to 5 genes of interest provided on the TRF were closely reviewed and all clinically significant variants are included on the report. As new scientific information becomes available on a regular basis, this could alter the interpretation of previously reported results. In the event of a change in interpretation, an unsolicited reclassification/amended report may be issued to the ordering clinician. Secondary findings within the ACMG recommended gene list are reported separately unless opted out (Kalia, 2017; Lee, 2025). Expanded childhood onset secondary findings are also available for prenatal exome orders. Gender identity (if provided) is not used in the interpretation of results, and sex assigned at birth is used in the interpretation of results only when necessary.

Test Limitations: This test was developed and its performance characteristics determined by Ambry Genetics. It has not been cleared or approved by the US Food and Drug Administration (FDA), which does not require this test to go through premarket review. It should not be regarded as investigational or for research. This test should be interpreted in context with other clinical findings and does not represent medical advice. Any questions or concerns regarding interpretation of results should be referred to a genetic counselor, medical geneticist, or other skilled medical provider. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. The following types of variants are detectable: nucleotide substitutions, small deletions/insertions, small indels, and gross deletions/duplications. The overall coverage of each gene varies and each individual may have slightly different coverage yield. Accurate exon-level gross deletion and duplication detection depends on several factors such as inherent sequence properties of the targeted regions, including shared homology, exon size, depth-of-coverage, capture efficiency, and degree of read depth variation in the reference samples. Therefore, the specificity and sensitivity of gross deletions and duplications may be reduced. Exome sequencing is not intended to analyze the following types of variants: gross rearrangements, deep intronic variations, long repeat sequences, portions of genes with highly homologous pseudogenes, trinucleotide repeat sequences, variants involved in tri-allelic inheritance, certain mitochondrial genome variants, epigenetic effects, oligogenic inheritance, and X-linked recessive variants in females who manifest disease due to skewed X-inactivation. A negative result from the analysis cannot rule out the possibility that the tested individual carries a rare undetected variant. Although molecular tests are highly accurate, rare diagnostic errors may occur such as sample mix-up, erroneous paternity identification, technical errors, clerical errors, and genotyping errors. Genotyping errors can result from trace contamination of PCR reactions, rare genetic variants that may interfere with analysis, or other sources.

Methodology: Genomic deoxyribonucleic acid (gDNA) is isolated from the patient's provided specimen. Samples are prepared using the IDT xGen Exome Research Panel V1.0 (IDT). Each DNA sample is sheared, adaptor ligated, PCR-amplified and incubated with exome baits. Captured DNA is eluted and PCR amplified. Final quantified libraries are seeded onto an Illumina flow cell and sequenced using paired-end, 150 cycle chemistry on the Illumina NovaSeq, NextSeq or HiSeq. Initial data processing, base calling, alignments and variant calls are generated by various bioinformatics tools using genome assembly GRCh37/hg19. Data is annotated with the Ambry Variant Analyzer tool (AVA), including: nucleotide and amino acid conservation, population frequency, and predicted functional impact. Data analysis is focused on small insertions and deletions, canonical splice site variants, and non-synonymous variants. Gross deletion/duplication analysis is assessed for proband only for genes within the targeted exome using a custom pipeline based on coverage and/or breakpoint analysis from NGS data and is followed by a confirmatory orthogonal method as needed. The following sites are used to search for previously described variants: the Human Gene Mutation Database (HGMD), gnomAD, and online search engines (e.g., PubMed). Variants are then filtered further based on applicable inheritance models. Co-segregation studies are performed if family members are available. All relevant findings undergo confirmation either by automated fluorescence dideoxy (aka "Sanger") sequencing or via coverage and alternate read ratios above established confidence thresholds with manual review by molecular geneticists using integrated genomics software (IGV). Gross deletions/duplications are confirmed by SNP Microarray (Affymetrix® CytoScan™ HD Array), in-house targeted array, MLPA, or Sanger sequencing. Co-segregation results may be confounded by many factors which cannot be completely ruled out including reduced penetrance, age-of-onset, and/or variable expressivity. Relevant findings are evaluated from among the genes in Ambry's internal, dynamic gene database which classifies genes as characterized or uncharacterized Mendelian disease genes based on clinical validity (Smith, 2017). Characterized genes are those currently known to underlie at least one Mendelian genetic condition. Uncharacterized genes are those with no or insufficient evidence to be associated with a Mendelian genetic condition. Characterized genes are analyzed first, followed by reflex analysis of uncharacterized genes for potential identification of a candidate gene finding. The analysis of candidate gene findings is only performed when an informative trio is received for testing and focuses on *de novo*, autosomal recessive, or X-linked inherited variants. Each variant remaining after inheritance model filtering is manually analyzed to identify the most likely causative variant(s). Interpretation is based on the clinical and family information provided by the referring provider and the current genetic knowledge at the time of reporting. Screening and analysis of known mtDNA pathogenic variants related to the proband's clinical phenotype is included if ordered. Amplification of the entire mitochondrial genome is carried out by long distance PCR and sequencing of mtDNA is performed separately on Illumina MiSeq. If ordered, ribonucleic acid (RNA) is isolated from the patient's whole blood. RNA is converted to complementary DNA (cDNA) by reverse transcriptase polymerase chain reaction (RT-PCR). RNA analysis is performed for reportable germline DNA variants expected to affect splicing, provided such studies are likely to meaningfully inform variant classification. Variants in genes with limited expression in whole blood, limited gene-disease validity, or an inconsistent mechanism of disease do not qualify for RNA analysis. Additionally, secondary findings variants do not qualify for RNA analysis. For eligible variants, primers are designed to amplify the relevant region of the pertinent gene from cDNA. The splicing patterns in variant carriers are then compared to control individuals to identify aberrant splicing. The presence of aberrantly spliced RNA transcripts meeting quality thresholds is incorporated as evidence for the assessment and classification of the DNA variants.

Analysis of Variants: The following lines of evidence are used to assess the pathogenicity of a variant: presence in affected and healthy populations, co-segregation, functional studies, variant type, conservation, in silico predictions, and presence in a functional protein domain.

Analytical range: Approximately 75% of bases are expected to have quality scores of Q30 or higher, which translates to a base-calling error rate of 1:1000 and accuracy of 99.9%. Additionally, 90% and 95% of the exome will be covered at ≥20x and ≥10x respectively under current run conditions, generally sufficient for high quality heterozygous and homozygous variant calling for germline variants. For any given individual ~10% of the targeted exome is not sequenced well enough to make a confident call. Each individual may have slightly different coverage yield distributions within the exome. Exons plus at least 2 bases into the 5' and 3' ends of all the introns are analyzed and reported. The pipeline detects deletions and duplications >5 exons in size in sequences with sufficient resolution. The minimum depth of coverage for targeted mitochondrial bases is 1,000X.

Ambry Genetics®

Understanding Your Positive Exome Sequencing Test Result

INFORMATION FOR PATIENTS WITH ONE OR MORE POSITIVE RESULTS

Genes	Genes are instructions for how our bodies work and develop. Everyone has two copies of each gene, one from each parent. Variants (changes) in certain genes can cause genetic conditions. These gene changes may be passed down in families or not. Even if there is no history of the specific condition in your family, it can still be caused by a change in a gene.
Exome Sequencing	Exome sequencing is a test designed to look for genetic changes in genes that may be the cause of an existing medical condition. Some genetic tests just look for common mutations, while others may just look for changes in common genes. Exome sequencing analyzes all genes known to cause medical conditions.
Result	Exome sequencing found one or more variants (or changes) in one or more genes that are known to be associated with your existing medical condition.
Cause	The test result confirms a genetic cause of your medical condition. Sometimes, genetic conditions can put a person at increased risk of other medical problems later in life. Talk with your healthcare provider to learn more about whether additional medical screening may be considered.
Patient for Life	As part of Ambry's Patient for Life program, we keep your results on file. Future genetic discoveries may provide enough information to update your result. We will notify your healthcare provider if any other clinically significant results are identified in the future.
Management Options	Management and treatment options vary by condition and other factors. Knowing the genetic cause of your medical condition may also help to avoid some tests or procedures. Talk to your healthcare provider about which management options may be right for you.
Family Members	Many people with a genetic condition are the first person in their family to have it. Often, genetic testing can find a gene change in someone even if the gene change was not found in other family members and was not passed down from a parent. In other families, gene changes can be passed down from parent to child. Talk to your healthcare provider about how the specific genetic condition may run in your family and what this means for the rest of your family. It is recommended that you share this information with your family members so they can learn more and discuss with their healthcare providers.

Please discuss this information with your healthcare provider. The field of genetics is continuously changing, so updates related to your genetic testing result, medical recommendations, and/or potential treatments may be available over time. This information is not meant to replace a discussion with a healthcare provider, and should not be considered or interpreted as medical advice.

One Enterprise, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 **ambrygen.com**

MKT-SPEC-FLYR-50040-EN v1 09.26.23